Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 7/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | STAT6 | P42226 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dehydrocostuslactone SCHEMBL699070 | 0.83 | CYP19A1 (0.46) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| Dehydrocostuslactone SCHEMBL936050 | 0.83 | CYP19A1 (0.46) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| Dehydrocostuslactone SCHEMBL31029489 | 0.83 | CYP19A1 (0.46) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| Isozaluzanin C SCHEMBL24453721 | 0.75 | PKM (0.40) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| Isozaluzanin C SCHEMBL17214374 | 0.75 | PKM (0.40) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| SCHEMBL10307518 | 0.74 | MAPT (0.32) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL17214363 | 0.69 | PKM (0.38) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| SCHEMBL18501586 | 0.69 | PKM (0.38) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| SCHEMBL17214369 | 0.69 | PKM (0.38) | CYP19A1PKMNLRP3ALDH1A1LMNA | |
| SCHEMBL22305504 | 0.68 | PTGS2 (0.40) | CYP19A1PKMNLRP3CYP3A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364069-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR | UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS (KR) | 2023-11-16 | — | — | US | claimed |
| EP-4248957-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-? RECEPTOR INHIBITOR | University Industry Foundation, Yonsei University Wonju Campus (KR) | 2023-09-27 | — | — | EP | claimed |
| WO-2022270760-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-Β RECEPTOR INHIBITOR | 연세대학교 원주산학협력단 | 2022-12-29 | — | — | WO | claimed |
| CN-120591331-B | Application of OsPUP gene or coded protein thereof in regulation of rice plant type and/or grain type | 湖南农业大学 | 2026-05-22 | — | — | CN | disclosed |
| US-20260130864-A1 | METHOD AND COMPOSITION FOR ENHANCING EXERCISE PERFORMANCE | NANJING NUTRABUILDING BIO TECH CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-12570657-B2 | Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-03-10 | — | — | US | disclosed |
| WO-2025011534-A1 | METHOD AND COMPOSITION FOR ENHANCING ATHLETIC PERFORMANCE | 南京纽邦生物科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-118209654-B | Method for simultaneously detecting four cytokinins in litchi by UPLC-MS/MS | 华南农业大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-118209654-A | Method for simultaneously detecting four cytokinins in litchi by UPLC-MS/MS | 华南农业大学 | 2024-06-18 | — | — | CN | disclosed |
| US-20240074434-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2024-03-07 | — | — | US | disclosed |
| US-20240065262-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4153592-A1 | MESYLATE SALTS OF HETEROCYCLIC CYTOKININS, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022270760-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-Β RECEPTOR INHIBITOR | 연세대학교 원주산학협력단 | 2022-12-29 | — | — | WO | disclosed |
| US-20220272987-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY H (US) | 2022-09-01 | — | — | US | disclosed |
| CN-112587517-B | Antibacterial application of dehydromesodermin C | 中国人民解放军空军军医大学 | 2022-03-01 | — | — | CN | disclosed |
| US-9670226-B2 | Sesquiterpenoids | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-06-06 | — | — | US | disclosed |
| US-9670226-B2 | Sesquiterpenoids | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-06-06 | — | — | US | disclosed |
| US-20170044180-A1 | Sesquiterpenoids | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-02-16 | — | — | US | disclosed |
| US-20170044180-A1 | Sesquiterpenoids | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-02-16 | — | — | US | disclosed |
| WO-2015161824-A2 | SESQUITERPENOIDS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130864-A1 | METHOD AND COMPOSITION FOR ENHANCING EXERCISE PERFORMANCE | SLC6A3, IL17A, HSD17B13 | CYP19A1 393/4885PKM 1548/4885NLRP3 3564/4885 |
| US-20170044180-A1 | Sesquiterpenoids | NFKBIA, RELA, IKBKG | CYP19A1 784/4885PKM 3075/4885NLRP3 192/4885 |
| US-20230364069-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR | TGFBR2, TGFBR1, TGFB1 | CYP19A1 2505/4885PKM 2672/4885NLRP3 1419/4885 |
| US-12570657-B2 | Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof | TYMP, TK1, DCK | CYP19A1 1346/4885PKM 671/4885NLRP3 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.